In Brief
Individual Diabetes Treatment
The DIRECT initiative brings together partners from the world of research and the pharmaceutical industry to jointly work on the development of medication and treatments for diabetes mellitus type 2 subtypes with the objective of more efficient help for patients. The project is funded by the Innovative Medicines Initiative. The total amount of funding at the initiative's disposal is 45 million Euro, 2.4 million Euro of which go to the Helmholtz Zentrum München. The aim of DIRECT is to define the various diabetes mellitus type 2 subtypes, to determine and develop biomarkers or test procedures for early diagnosis and the establishment of potential personalised forms of treatment. To this end, the approximately 150 scientists involved in the project will evaluate phenotypical and genetic data of more than 100,000 samples from diabetes mellitus type 2 patients. The project is scheduled to run over a period of seven years.
